文献速递认知障碍与痴呆

氯沙坦减少临床诊断阿尔茨海默病脑萎缩的安全性和有效性(RADAR试验):双盲随机安慰剂对照2期试验

Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
PubMed 文献 · Lancet Neurol · 2021-01-01

RADAR试验纳入211例轻中度阿尔茨海默病患者,随机接受氯沙坦100mg/d或安慰剂治疗12个月,主要终点为全脑体积变化。

要点

  • 氯沙坦100mg/d治疗12个月未显著减少轻中度AD患者全脑萎缩。
  • 两组不良事件数量低且无差异,各有一例治疗相关死亡。
  • 未来需研究更早期干预或更长疗程的潜在获益。

核心结论

  • 氯沙坦治疗12个月耐受性良好,但未能有效减少临床诊断轻中度阿尔茨海默病患者的脑萎缩速率。

研究设计与样本

  • 双盲、多中心、随机安慰剂对照2期试验,从英国23家NHS医院信托招募55岁及以上、未用过血管紧张素II药物、符合NINCDS-ADRDA标准的轻中度阿尔茨海默病患者。
  • 经4周开放标签活性治疗和洗脱后,按1:1随机分配至口服氯沙坦100mg(初始两剂滴定)或匹配安慰剂每日一次,治疗12个月。
  • 随机化按年龄和基线内侧颞叶萎缩评分最小化,通过在线或电话PIN接入服务进行;参与者、研究伙伴和研究人员对分组设盲。
  • 主要终点为基线至12个月全脑体积变化,采用容积MRI和边界移位区间(BSI)分析,按意向治疗原则分析(无缺失数据填补)。
  • 2014年7月22日至2018年5月17日,261例进入开放标签阶段,211例随机分配(氯沙坦n=105,安慰剂n=106);197例(93%)完成研究,171例(81%)有完整主要终点数据。

主要发现

  • 不良事件数量低(氯沙坦组22例,安慰剂组20例),治疗组间无差异;每组各有一例治疗相关死亡。

临床怎么用

  • 不推荐将氯沙坦用于减少轻中度阿尔茨海默病患者的脑萎缩速率。
  • 氯沙坦在该人群中的安全性与安慰剂相当,但无疾病修饰疗效证据。

局限性

  • 研究纳入临床诊断的轻中度阿尔茨海默病患者,未涉及更早期或轻度认知障碍人群。
  • 治疗期限为12个月,无法评估更长疗程的潜在效果。
  • 主要终点分析仅基于171例(81%)有完整数据的参与者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drugs modifying angiotensin II signalling could reduce Alzheimer's disease pathology, thus decreasing the rate of disease progression. We investigated whether the angiotensin II receptor antagonist losartan, compared with placebo, could reduce brain volume loss, as a measure of disease progression, in clinically diagnosed mild-to-moderate Alzheimer's disease. METHODS: In this double-blind, multicentre, randomised controlled trial, eligible patients aged 55 years or older, previously untreated with angiotensin II drugs and diagnosed (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria) with mild-to-moderate Alzheimer's disease, and who had capacity to consent, were recruited from 23 UK National Health Service hospital trusts. After undergoing a 4-week, open-label phase of active treatment then washout, participants were randomly assigned (1:1) oral over-encapsulated preparations of either 100 mg losartan (after an initial two-dose titration stage) or matched placebo daily for 12 months. Randomisation, minimised by age and baseline medial temporal lobe atrophy score, was undertaken online or via pin-access service by telephone. Participants, their study companions, and study personnel were masked to group assignment. The primary outcome, analysed by the intention-to-treat principle (ie, participants analysed in the group to which they were randomised, without imputation for missing data), was change in whole brain volume between baseline and 12 months, measured using volumetric MRI and determined by boundary shift interval (BSI) analysis. The trial is registered with the International Standard Randomised Controlled Trial Register (ISRCTN93682878) and the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT 2012-003641-15), and is completed. FINDINGS: Between July 22, 2014, and May 17, 2018, 261 participants entered the open-label phase. 211 were randomly assigned losartan (n=105) or placebo (n=106). Of 197 (93%) participants who completed the study, 171 (81%) had complete primary outcome data. The mean brain volume (BSI) reduction was 19·1 mL (SD 10·3) in the losartan group and 20·0 mL (10·8) in the placebo group. The difference in total volume reduction between groups was -2·29 mL (95% CI -6·46 to 0·89; p=0·14). The number of adverse events was low (22 in the losartan group and 20 in the placebo group) with no differences between treatment groups. There was one treatment-related death per treatment group. INTERPRETATION: 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild-to-moderate Alzheimer's disease. Further research is needed to assess the potential therapeutic benefit from earlier treatment in patients with milder cognitive impairment or from longer treatment periods. FUNDING: Efficacy and Mechanism Evaluation Programme (UK Medical Research Council and National Institute for Health Research).

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Kehoe PG, Turner N, Howden B, et al. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2021. PMID: 34687634. doi:10.1016/S1474-4422(21)00263-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。